

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Bill E. Cham and Jo-Ann Maltais)	
)	Art Unit: Not yet assigned
Serial No. Not yet assigned)	
)	Examiner: Not yet assigned
Filed: June 20, 2003)	
)	
For: A Method of Treating and Preventing)	
Infectious Diseases Via Creation of a)	
Modified Viral Particle with)	
Immunogenic Properties)	

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,



John K. McDonald, Ph.D.
Reg. No. 42,860

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 13131-0310 (44378-282108)

Express Mail Label No. EV 334683633US
Filed June 20, 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Not yet assigned
		Filing Date	June 20, 2003
		First Named Inventor	BILL E. CHAM
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 1	of 2	Attorney Docket Number	13131-0310 (44378-282108)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	4,481,189		PRINCE	11-06-1984	
	2	4,522,809		ADAMOWICZ, et al.	06-11-1985	
	3	4,540,401		MARTEN	09-10-1985	
	4	4,540,573		NEURATH, et al.	09-10-1985	
	5	4,591,505		PRINCE	05-27-1986	
	6	4,613,501		HOROWITZ	09-23-1986	
	7	4,615,886		PURCELL, et al.	10-07-1986	
	8	4,643,718		MARTEN	02-17-1987	
	9	4,895,558		CHAM	02-23-1990	
	10	4,909,940		HOROWITZ, et al.	03-20-1990	
	11	4,923,439		SEIDEL, et al.	05-08-1990	
	12	5,116,307		COLLINS	05-26-1992	
	13	5,256,767		SALK, et al.	10-26-1993	
	14	5,419,759		NAFICY	05-30-1995	
	15	5,484,396		NAFICY	02-16-1996	
	16	5,698,432		OXFORD	12-16-1997	
	17	5,719,194		MANN, et al.	02-17-1998	
	18	5,744,038		CHAM	04-28-1998	
	19	5,853,725		SALK et al.	12-29-1998	
	20	5,877,005		CASTOR	03-02-1999	
	21	5,885,578		SALK et al.	03-23-1999	
	22	5,895,650		SALK et al.	04-20-1999	
	23	5,911,698		CHAM	06-15-1999	
	24	5,916,806		SALK et al.	06-29-1999	
	25	5,928,930		SALK et al.	07-27-1999	
	26	6,017,543		SALK et al.	01-25-2000	
	27	6,136,321		BARRETT, et al.	10-24-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	28		CA 1271708		REINHARD, et al.	07-17-1990		
	29		WO 01/45718		ARUBA INTERNATIONAL PTY LTD	06-28-2001		

Examiner Signature	Date Considered
-----------------------	--------------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Not yet assigned
		Filing Date	June 20, 2003
		First Named Inventor	BILL E. CHAM
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2	of 2	Attorney Docket Number	13131-0310 (44378-282108)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	30 /	AGNESE, S.T., et al., "Evaluation of Four Reagents for Dilipidation of Serum," Clin Biochem., (1983) Apr., Vol. 16, No. 2, pp. 98-100.	
	31 /	CHAM, BILL E., et al., "Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals," Journal of Clinical Apheresis, Vol. 10, 1995, pp. 61-69.	
	32 /	CHAM, BILL E., et al., "A solvent system for delipidation of plasma or serum without protein precipitation," Journal of Lipid Research, Vol. 17, 1976, pp. 176-181.	
	33 /	DEVA, A.K., et al., "Establishment of an in-use testing method for evaluating disinfection of surgical instruments using the duck hepatitis B model," J. Hosp. Infect., (1996) June, Vol. 22, No. 2, pp. 119-130, Abstract only.	
	34 /	FEINSTONE, STEPHEN M., et al., "Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform," Infection and Immunity, August 1983, Vol. 41, No. 2, pp. 816-821.	
	35 /	HOROWITZ, B., et al., "Viral safety of solvent/detergent-treated blood products," Blood Coagulation and Fibrinolysis," Vol. 5, Suppl. 3, 1994, pp. S21-S28.	
	36 /	KLIMOV, A.N. et al., "Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized Plasma into the Body as a Possible Means to Treat Atherosclerosis," Russian Journal Kardiologia, Vol. 18, No. 6, pp. 23-29 (1978).	
	37 /	NGU, V.A., "Chronic Infections from the Perspective of Evolution: a Hypothesis", <i>Medical Hypotheses</i> , Vol. 42, pp. 81-88 (1994).	
	38 /	NGU, V.A., "Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens", <i>Medical Hypotheses</i> , Vol. 39, pp. 17-21 (1992).	
	39 /	NGU, V.A., "The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune response to the virus", <i>Medical Hypotheses</i> , Vol. 48, pp. 517-521 (1997).	
	40	PARKER, THOMAS S., et al., "Plasma high density lipoprotein is increased in man when low density lipoprotein (LDL) is lowered by LDL-pheresis," Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 771-781, February 1986.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.